| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
2
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
3
|
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
|
J Exp Med
|
2000
|
16.09
|
|
4
|
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
|
JAMA
|
2006
|
8.15
|
|
5
|
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
|
J Clin Oncol
|
2008
|
8.09
|
|
6
|
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
|
J Exp Med
|
1999
|
7.94
|
|
7
|
A randomized trial of surgery in the treatment of single metastases to the brain.
|
N Engl J Med
|
1990
|
7.92
|
|
8
|
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
|
Lancet
|
2004
|
7.78
|
|
9
|
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
|
J Clin Oncol
|
2006
|
7.33
|
|
10
|
Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.
|
JAMA
|
1998
|
6.49
|
|
11
|
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
|
J Clin Oncol
|
1999
|
5.95
|
|
12
|
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
|
Clin Cancer Res
|
2007
|
5.51
|
|
13
|
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
|
Int J Radiat Oncol Biol Phys
|
2000
|
5.06
|
|
14
|
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
|
Cancer
|
1996
|
4.46
|
|
15
|
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
|
Proc Natl Acad Sci U S A
|
2008
|
4.43
|
|
16
|
Prognostic factors in 1,521 melanoma patients with distant metastases.
|
J Am Coll Surg
|
1995
|
4.37
|
|
17
|
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
|
Curr Opin Immunol
|
2006
|
3.12
|
|
18
|
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.
|
J Neurosurg
|
1998
|
3.11
|
|
19
|
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
|
Oncologist
|
2009
|
2.85
|
|
20
|
Phase I/II study of ipilimumab for patients with metastatic melanoma.
|
J Clin Oncol
|
2008
|
2.79
|
|
21
|
Whole-brain radiotherapy in the management of brain metastasis.
|
J Clin Oncol
|
2006
|
2.76
|
|
22
|
Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
|
J Neurosurg
|
2003
|
2.72
|
|
23
|
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.
|
Lab Invest
|
1996
|
2.31
|
|
24
|
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
|
J Leukoc Biol
|
2013
|
1.90
|
|
25
|
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
|
J Clin Oncol
|
2006
|
1.83
|
|
26
|
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
|
J Immunother
|
2004
|
1.77
|
|
27
|
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
|
Int J Radiat Oncol Biol Phys
|
1997
|
1.72
|
|
28
|
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.
|
Nat Clin Pract Oncol
|
2008
|
1.70
|
|
29
|
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.59
|
|
30
|
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
|
Nat Rev Neurol
|
2015
|
1.50
|
|
31
|
Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases.
|
J Clin Oncol
|
1998
|
1.49
|
|
32
|
Natural T cell immunity against cancer.
|
Clin Cancer Res
|
2003
|
1.36
|
|
33
|
CTLA-4 blockade: therapeutic potential in cancer treatments.
|
Onco Targets Ther
|
2010
|
1.33
|
|
34
|
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.
|
Clin Cancer Res
|
2009
|
1.31
|
|
35
|
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397).
|
J Clin Oncol
|
2005
|
1.28
|
|
36
|
Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.
|
Int J Radiat Oncol Biol Phys
|
1981
|
1.28
|
|
37
|
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2014
|
1.22
|
|
38
|
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.
|
Int J Radiat Oncol Biol Phys
|
2015
|
1.21
|
|
39
|
Immune modulation for cancer therapy.
|
Br J Cancer
|
2014
|
1.15
|
|
40
|
The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group.
|
Int J Radiat Oncol Biol Phys
|
1981
|
1.11
|
|
41
|
The treatment of brain metastases in melanoma patients.
|
Cancer Treat Rev
|
2004
|
1.08
|
|
42
|
Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis.
|
Am J Clin Oncol
|
2010
|
1.06
|
|
43
|
Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases.
|
Cancer
|
2007
|
1.06
|
|
44
|
Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.
|
BMC Cancer
|
2010
|
1.06
|
|
45
|
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
|
Arch Dermatol
|
2006
|
1.05
|
|
46
|
Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma.
|
J Neurosurg
|
2008
|
1.03
|
|
47
|
Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.
|
Br J Cancer
|
1996
|
1.03
|
|
48
|
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
|
Int J Radiat Oncol Biol Phys
|
2014
|
1.03
|
|
49
|
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
|
Semin Oncol
|
2010
|
1.02
|
|
50
|
Combinations of immunotherapy and radiation in cancer therapy.
|
Front Oncol
|
2014
|
1.01
|
|
51
|
Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.
|
Melanoma Res
|
2010
|
1.01
|
|
52
|
Value of radiation theray in the management of intracranial metastases.
|
Cancer
|
1961
|
1.00
|
|
53
|
Radiation therapy of cerebral metastases: a randomized prospective clinical trial.
|
Int J Radiat Oncol Biol Phys
|
1978
|
1.00
|
|
54
|
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
|
Br J Cancer
|
2000
|
0.98
|
|
55
|
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
|
Curr Opin Mol Ther
|
2005
|
0.98
|
|
56
|
Improvement in quality of survival following whole-brain irradiation for brain metastasis.
|
Radiology
|
1968
|
0.96
|
|
57
|
The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases.
|
Technol Cancer Res Treat
|
2003
|
0.95
|
|
58
|
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
|
Curr Oncol Rep
|
2013
|
0.94
|
|
59
|
Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases.
|
Radiother Oncol
|
1993
|
0.93
|
|
60
|
Targeted therapies in brain metastases.
|
Curr Treat Options Neurol
|
2014
|
0.93
|
|
61
|
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.
|
Vaccine
|
2015
|
0.92
|
|
62
|
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.
|
Neuro Oncol
|
2015
|
0.92
|
|
63
|
American College of Radiology appropriateness criteria on multiple brain metastases.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.91
|
|
64
|
Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.
|
Strahlenther Onkol
|
1994
|
0.91
|
|
65
|
Modern multidisciplinary management of brain metastases.
|
Curr Oncol Rep
|
2010
|
0.89
|
|
66
|
ACR Appropriateness Criteria: single brain metastasis.
|
Curr Probl Cancer
|
2010
|
0.89
|
|
67
|
A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision.
|
Radiother Oncol
|
2008
|
0.87
|
|
68
|
The past, present and future of immunotherapy against tumor.
|
Transl Lung Cancer Res
|
2015
|
0.85
|
|
69
|
Current neurosurgical management of brain metastases.
|
Semin Oncol
|
2008
|
0.83
|
|
70
|
Gamma knife radiosurgery for malignant melanoma brain metastases.
|
Clin Neurosurg
|
2007
|
0.83
|
|
71
|
Ipilimumab and whole brain radiation therapy for melanoma brain metastases.
|
J Neurooncol
|
2014
|
0.82
|
|
72
|
Systemic Immunotherapy for the Treatment of Brain Metastases.
|
Front Oncol
|
2016
|
0.82
|
|
73
|
Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases.
|
Med Oncol
|
2010
|
0.81
|
|
74
|
Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.
|
Brain Tumor Res Treat
|
2013
|
0.80
|
|
75
|
The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.
|
Oncologist
|
2016
|
0.79
|
|
76
|
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.
|
Front Oncol
|
2016
|
0.78
|
|
77
|
Clinical trials in melanoma patients with brain metastases.
|
Pigment Cell Melanoma Res
|
2015
|
0.78
|
|
78
|
Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
|
Radiat Oncol
|
2015
|
0.77
|
|
79
|
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
|
Hum Vaccin Immunother
|
2016
|
0.75
|
|
80
|
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.
|
Neuro Oncol
|
2015
|
0.75
|
|
81
|
The role of checkpoints in the treatment of GBM.
|
J Neurooncol
|
2015
|
0.75
|
|
82
|
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.
|
Int J Mol Sci
|
2016
|
0.75
|
|
83
|
Embracing rejection: Immunologic trends in brain metastasis.
|
Oncoimmunology
|
2016
|
0.75
|